Rejuve Therapeutics is developing a groundbreaking treatment for COPD, the 3rd leading cause of death worldwide. Affecting 20M Americans and 500M globally, COPD currently has no cure and is treated with potent drugs that only alleviate symptoms and have severe side effects. Rejuve’s solution, a unique peptide delivered via dry powder inhaler, can slow, stop, and even reverse the disease by 80% on average with almost no side effects. This innovation positions Rejuve as the first company to significantly reverse COPD and capture major market share.
